Clinical Trial of Fresolimumab

A Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis


Study Overview

The purpose of this study was to assess the effectiveness of the medication Fresolimumab in treating patients with a diagnosis of steroid-resistant primary Focal Segmental Glomerulosclerosis (FSGS). The study involved being randomly assigned to receive either the study medication Fresolimumab or a placebo (sugar pill) for a designated length of time under close physician supervision. The goal is to achieve either partial or complete remission of proteinuria. Participants were followed for approximately 9 months after beginning study medication.

Eligibility Criteria

You might be eligible to participate in this study if you:
(1) Are age 18 or older
(2) Have had a kidney biopsy confirming primary FSGS
(3) Have taken steroids in the past and they are no longer helping treat your FSGS well
(4) Have a urine protein:creatinine ratio of > 3
(5) Have an estimated GFR > 30 ml/min/1.73m2
(6) Are willing to have additional lab tests completed to confirm eligibility

You cannot participate in this study if you:
(1) Have Type 1 or 2 diabetes mellitus or other condition that caused your FSGS
(2) Have had an organ transplant
(3) Have a history of cancer or a precancerous condition

Have questions?

For more information please contact:

Hailey Desmond, MS, CCRP
Phone: (734) 232-4851
Email: UMKidneyStudies@umich.edu



C-Probe Study Links